Search Results 701-710 of 18233 for Immunode

1. Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma. - Mayo Clinic

   Known seropositive for or active viral infection with hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodeficiency virus (HIV); Known sensitivity ...

2. Study of Iomab-B Prior to HCT vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory AML - Mayo Clinic

   Have current or prior positive test results for human immunodeficiency virus (HIV) or hepatitis B (HBV) or C. Subjects who have positive HBV test results ...

3. A Study Of CSF-1R Inhibitor, AXatilimab For GVHD After HLA-matched Related And Unrelated Donor Allogeneic Stem Cell Transplantation (ABRAXAS) - Mayo Clinic

   Any known infection with human immunodeficiency virus (HIV), HTLV-1. Uncontrolled bacterial, viral, or fungal infections (currently taking medication and ...

4. Phase II Study to Assess AFM13 in Patients With R/R CD30-positive T-cell Lymphoma or Transformed Mycosis Fungoides - Mayo Clinic

   Diagnosis of Human Immunodeficiency Virus (HIV) i.e. presence of HIV 1/2 antibodies; Diagnosis of immunodeficiency or requirement for systemic steroid ...

5. A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens - Mayo Clinic

   Known to be seropositive for human immunodeficiency virus; or; Known to be seropositive for hepatitis B (defined by a positive test for hepatitis B surface ...

6. Obeticholic Acid (OCA) in Primary Sclerosing Cholangitis (PSC) - Mayo Clinic

   Known history of human immunodeficiency virus (HIV) infection; Currently experiencing, or experienced within ≤1 month of screening, moderate to severe ...

7. Phase 3 Study of Vimseltinib for Tenosynovial Giant Cell Tumor - Mayo Clinic

   Known active human immunodeficiency virus (HIV), active or chronic hepatitis B, active or chronic hepatitis C, or known active mycobacterium tuberculosis ...

8. A Study to Evaluate Firstline Pembrolizumab Alone or in Combination with Pemetrexed and Carboplatin in Induction/Maintenance or Postprogression in Treating Patients with Stage IV Non-squamous Non-small Cell Lung Cancer - Mayo Clinic

   Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this ...

9. A Study to Evaluate the Effectiveness and Safety of Pembrolizumab Combined with Bacillus Calmette-Guerin in High-Risk Non-Muscle Invasive Bladder Cancer - Mayo Clinic

   - Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days of start ...

10. A Study to Evaluate AVID200 in Myelofibrosis Patients - Mayo Clinic

    Known history of human immunodeficiency virus (HIV), or known active hepatitis A, B, or C infection. Organ transplant recipients other than bone marrow ...